Eli Lilly (NYSE:LLY) announced that its financial results for Q1 2025, prepared under the U.S. generally accepted accounting ...

Eli Lilly’s stock took a 4.6% dive after Morgan Stanley gently tapped the brakes on its optimism, lowering its price target ...

The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs ...

“One would expect that companies that pay dividends are more stable and have lower growth rates. As a result, they should rally less in up markets and decline less in down markets. In other words, ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...

Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.